BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 15923705)

  • 21. Tay-Sachs disease in persons of French-Canadian heritage in northern New England.
    Palomaki GE; Williams J; Haddow JE; Natowicz MR
    Am J Med Genet; 1995 May; 56(4):409-12. PubMed ID: 7604851
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The prevention of the thalassemia maior: emergent problems.
    Maffei L; Foglietta E; Cappabianca MP; Lerone M; Mastropietro F; Bianco I
    Haematologica; 2002 Dec; 87(12):ELT44. PubMed ID: 12495913
    [No Abstract]   [Full Text] [Related]  

  • 23. Screening for carriers of Tay-Sachs disease: two approaches.
    Clarke JT
    Can Med Assoc J; 1978 Sep; 119(6):549-50. PubMed ID: 709442
    [No Abstract]   [Full Text] [Related]  

  • 24. The ovrselling of genetic anxiety.
    Goodman MJ; Goodman LE
    Hastings Cent Rep; 1982 Oct; 12(5):20-7. PubMed ID: 7174291
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic testing-genetic counseling: to keep thalassemia at bay.
    Gupta A; Hattori Y; Agarwal S
    Genet Couns; 2003; 14(4):435-6. PubMed ID: 14738119
    [No Abstract]   [Full Text] [Related]  

  • 26. Molecular analysis of the HEXA gene in Italian patients with infantile and late onset Tay-Sachs disease: detection of fourteen novel alleles.
    Montalvo AL; Filocamo M; Vlahovicek K; Dardis A; Lualdi S; Corsolini F; Bembi B; Pittis MG
    Hum Mutat; 2005 Sep; 26(3):282. PubMed ID: 16088929
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tay-Sachs disease prevention in Minnesota. Role of physician advocacy in carrier screening.
    Lipsitz DJ; Anderson VE; O'Brien JF; Desnick RJ
    Minn Med; 1986 May; 69(5):272-5. PubMed ID: 3736533
    [No Abstract]   [Full Text] [Related]  

  • 28. Biomedical genetics of the inherited metabolic diseases: the GM2-gangliosidoses.
    Kolodny EH
    Am J Ment Defic; 1984 Mar; 88(5):582-9. PubMed ID: 6428229
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevention of beta-thalassemia in a large Pakistani family through cascade testing.
    Baig SM; Din MA; Hassan H; Azhar A; Baig JM; Aslam M; Anjum I; Farooq M; Hussain MS; Rasool M; Nawaz S; Qureshi JA; Zaman T
    Community Genet; 2008; 11(1):68-70. PubMed ID: 18196920
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Knowledge and attitudes toward Tay-Sachs disease among a college student population.
    Austein CF; Seashore MR; Mick SS
    Yale J Biol Med; 1981; 54(5):345-54. PubMed ID: 7336765
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Future perspectives for Tay-Sachs disease.
    Desnick RJ; Kaback MM
    Adv Genet; 2001; 44():349-56. PubMed ID: 11596996
    [No Abstract]   [Full Text] [Related]  

  • 32. Seven years experience with Tay-Sachs screening in Florida.
    Tocci PM
    J Fla Med Assoc; 1981 Jan; 68(1):24-9. PubMed ID: 7217914
    [No Abstract]   [Full Text] [Related]  

  • 33. The rabbi's dilemma. [Interview by Alison George].
    Ekstein J
    New Sci; 2004 Feb 14-20; 181(2434):44-7. PubMed ID: 15085821
    [No Abstract]   [Full Text] [Related]  

  • 34. Impact of a national beta-thalassemia carrier screening program on the birth rate of thalassemia major.
    Chern JP; Lin KH; Su YN; Lu MY; Jou ST; Lin DT; Wang SC; Lin KS
    Pediatr Blood Cancer; 2006 Jan; 46(1):72-6. PubMed ID: 16206199
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Tay-Sachs disease screening program in the U.S. as a model for the control of genetic disease: an historical view.
    Edelson PJ
    Health Matrix Clevel; 1997; 7(1):125-33. PubMed ID: 10167171
    [No Abstract]   [Full Text] [Related]  

  • 36. The clinical significance of the spectrum of interactions of CAP+1 (A-->C), a silent beta-globin gene mutation, with other beta-thalassemia mutations and globin gene modifiers in north Indians.
    Garewal G; Das R; Awasthi A; Ahluwalia J; Marwaha RK
    Eur J Haematol; 2007 Nov; 79(5):417-21. PubMed ID: 17900295
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Community-based genetic education: sources of information in a Tay Sachs disease screening program.
    Clark M; Palmer R; Kontras S
    Ohio State Med J; 1982 Mar; 78(3):218-20. PubMed ID: 7078924
    [No Abstract]   [Full Text] [Related]  

  • 38. Screening for genetic diseases.
    Motulsky AG
    N Engl J Med; 1997 May; 336(18):1314-6. PubMed ID: 9113938
    [No Abstract]   [Full Text] [Related]  

  • 39. A novel HEXA mutation [1393G>A (D465N)] in a Mexican Tay-Sachs disease patient.
    Alvarez-Rodríguez A; Triggs-Raine B; Barros-Núñez P; Lozano CM
    Hum Mutat; 2001 May; 17(5):437. PubMed ID: 11317368
    [No Abstract]   [Full Text] [Related]  

  • 40. Confidential Tay-Sachs carrier screening.
    Rosner F
    N Y State J Med; 1989 Oct; 89(10):585. PubMed ID: 2608220
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.